A fagen endoscopes na likitanci na cikin gida, samfuran da aka shigo da su sun daɗe suna mamaye duka masu sassauƙa da Rigid. Koyaya, tare da ci gaba da haɓaka ingancin cikin gida da saurin ci gaban maye gurbin shigo da kayayyaki, Sonoscape da Aohua sun yi fice a matsayin kamfanoni masu wakilci a fagen sassauƙan endoscopes.
Kasuwancin endoscope na likitanci har yanzu yana mamaye da shigo da kaya
Gabaɗaya matakin fasaha da tsarin aikin masana'antu na masana'antar endoscope na likitancin kasar Sin sun daɗe baya bayan na ƙasashen da suka ci gaba, amma kamfanoni da yawa sun sami babban ci gaba a wasu ƙananan sassa, sannu a hankali sun kama manyan samfuran da aka shigo da su daga tsaka-tsaki zuwa na ƙarshe a cikin ainihin ma'auni kamar bayyana hoto da haɓaka launi. A shekara ta 2017, adadin masana'antar endoscopy na likitancin kasar Sin ya kai kashi 3.6%, wanda ya karu zuwa kashi 6.9 a shekarar 2021, kuma ana sa ran zai kai kashi 35.2% a shekarar 2030.
Adadin cikin gida na endoscopes na likita a China(Shigo da & Na gida)
Rigid Endoscope: A cikin 2022, girman kasuwar kasuwar ƙwanƙwasa ta kasar Sin ya kai kusan yuan biliyan 9.6, kuma samfuran da aka shigo da su kamar Karl Storz, Olympus, Stryker, da Wolf suna da adadin kashi 73.4% na kasuwar kasuwa. Samfuran cikin gida sun fara a makare, amma kamfanonin cikin gida da Mindray ke wakilta sun tashi da sauri, suna lissafin kusan kashi 20% na kasuwar kasuwa.
Flexibe Endoscope: A shekarar 2022, girman kasuwar kasuwar endoscope na kasar Sin ya kai kusan yuan biliyan 7.6, kuma alamar Olympus da aka shigo da ita ita kadai, wacce ta kai kashi 60.40% na kasuwar cikin gida, kuma Fuji na Japan ya zo na biyu da kashi 14%. Kamfanonin cikin gida da ke wakiltaSonoscapekuma Aohua ya karya ka'idojin fasaha na kasashen waje kuma ya tashi cikin sauri. A shekarar 2022, Sonoscape ya zama na farko a kasar Sin da kashi 9% da na uku a kasuwa; Aohua ya zo na biyu a kasar Sin da kashi 5.16% kuma na biyar a kasuwa.
Matrix samfurin
Aohua yana mai da hankali kan magunguna masu sassauƙa na endoscopes da abubuwan da ake amfani da su. Ana amfani da samfuransa sosai a sassan asibiti kamar gastroenterology, likitan numfashi, otolaryngology, gynecology, da magungunan gaggawa.
Kamfanin ya kafa manyan layukan samfur guda huɗu, gami da duban dan tayi, endoscopy, aikin tiyata kaɗan, da sa baki na zuciya. An fara ƙirƙirar ƙirar haɓakar layin samfuri da yawa. Daga cikin su, kasuwancin endoscopy ya zama daya daga cikin manyan abubuwan da kamfanin ke da shi kuma shine tushen ci gaban kamfanin. Kasuwancin endoscopy na kamfanin ya dogara ne akan nau'ikan endoscopes masu sassauƙa, kuma ya haɗa da abubuwan da ake amfani da su na endoscopy da tsayayyen endoscopes.
Tsarin samfurin Endoscope mai sassauƙa na kowane kamfani
Sonoscape da Aohua duka sun samar da cikakken tsarin samfurin a fagen endoscopes mai laushi, kuma tsarin tsarin samfurin su yana kusa da na Olympus, jagoran duniya a cikin masu sassaucin ra'ayi.
Samfurin flagship na Aohua AQ-300 yana matsayi a cikin babban kasuwa, AQ-200 tare da daidaiton aiki da farashi yana nufin kasuwar tsakiyar ƙarshen, kuma samfuran asali kamar AQ-120 da AQ-100 sun dace da kasuwar ƙasa.
Sonoscape's m endoscope samfurin HD-580 an sanya shi a cikin babban kasuwa, kuma samfurin yau da kullun akan siyarwa shine HD-550, wanda yake a tsakiya. Yana da wadataccen tanadin samfura a cikin ƙananan kasuwanni da tsakiyar-ƙarshen.
Kwatancen aiki na tsaka-tsaki da ƙarshen ƙarshen ƙarshen
Manyan samfuran endoscope na Sonoscape da Aohua sun riga sun ci karo da manyan samfuran duniya a fannoni da yawa na aiki. Ko da yake an inganta samfurori masu mahimmanci na biyu a kasuwa na ɗan gajeren lokaci, suna ci gaba da sauri a cikin kasuwa mai mahimmanci ta hanyar dogara ga inganci mai kyau da kuma farashi mai tsada.
A halin yanzu, kasuwannin cikin gida na Aohua da Sonoscape galibi suna cikin manyan asibitoci da sakandare. A sa'i daya kuma, bisa dogaro da kaddamar da kayayyaki masu inganci, sun yi saurin kwace babbar kasuwar da ke sama da manyan makarantu a cikin 'yan shekarun nan, kuma kasuwar ta samu karbuwa sosai. Daga cikin su, Sonoscape endoscopes sun shiga asibitoci fiye da 400 ta 2023; Aohua ya dogara da haɓaka tsarin AQ-300 4K ultra high-definition endoscope a cikin 2024, kuma ya sanya (ciki har da cin nasara) asibitocin manyan makarantu 116 a waccan shekarar (an shigar da asibitoci 73 da 23 a cikin 2023 da 2022 bi da bi).
Kudin shiga aiki
A cikin 'yan shekarun nan, ayyukan Sonoscape da Aohua suna girma cikin sauri, musamman a cikin kasuwancin da suka shafi endoscopy. Ko da yake za a sami sauyi a cikin 2024 saboda tasirin manufofin masana'antu, aiwatar da manufofin sabunta kayan aiki na gaba zai haifar da dawo da buƙatun kasuwa.
Kudaden da Aohua ta samu na endoscopy ya karu daga yuan miliyan 160 a shekarar 2018 zuwa yuan miliyan 750 a shekarar 2024. A shekarar 2020, sakamakon tasirin annobar, kudaden shiga na shekarar ya ragu da kashi 11.6%. Tun lokacin da aka fitar da manyan samfuran a cikin 2023, haɓakar aikin ya ƙara haɓaka. A cikin 2024, haɓakar haɓaka ya ragu saboda tasirin manufofin da suka shafi na'urorin likitancin cikin gida.
Jimlar kudaden shiga na Sonoscape Medical ya karu daga Yuan biliyan 1.23 a shekarar 2018 zuwa yuan biliyan 2.014 a shekarar 2024. Manufofin da suka danganci na'urar likita a cikin 2024, kasuwancin da ke da alaƙa da endoscopy ya ragu kaɗan.
Dangane da cikakken kudaden shiga na kamfanin, jimillar kasuwancin Sonoscape ya zarce na Aohua, amma yawan bunkasuwar sa ya dan yi kasa da na Aohua. Don kasuwancin endoscopy, kasuwancin da ke da alaƙa da endoscopy na Sonoscape har yanzu yana ɗan girma fiye da na Aohua. A cikin 2024, kudaden shiga na kasuwanci na Sonoscape da Aohua masu alaƙa da endoscopy zai zama miliyan 800 da miliyan 750 bi da bi; Dangane da haɓakar haɓaka, kasuwancin endoscopy na Sonoscape ya haɓaka da sauri fiye da Aohua kafin 2022, amma tun daga 2023, saboda haɓakar ƙarar samfuran manyan samfuran Aohua, ƙimar ci gaban Aohua ya zarce ƙimar kasuwancin endoscopy na Sonoscape.
Kwatanta kudaden shiga na aiki na Aohua da Sonoscape
( Yuan miliyan 100)
Kasuwancin endoscope na likitanci na cikin gida ya mamaye samfuran da aka shigo da su. Masana'antun cikin gida da Sonoscape da Aohua ke wakilta suna tashi cikin sauri kuma a hankali suna maye gurbin shigo da kaya. Kasuwancin cikin gida shine yanki mafi mahimmancin kasuwanci na Sonoscape da Aohua. A cikin 2024, kasuwancin cikin gida ya kai kashi 51.83% da 78.43% na yawan kasuwancin Sonoscape da Aohua bi da bi. A sa'i daya kuma, manyan kamfanonin cikin gida da Sonoscape da Aohua ke wakilta suna tura kasuwannin ketare, kuma yawan kasuwancin na'urorin likitanci na cikin gida a kasuwannin duniya na ci gaba da karuwa.
Kasuwancin endoscope na kasa da kasa na Aohua yana ci gaba da bunkasa, daga yuan miliyan 100 a shekarar 2020 zuwa yuan miliyan 160 a shekarar 2024, amma yawan kasuwancinsa na kasa da kasa ya ragu daga kashi 36.8% a shekarar 2020 zuwa kashi 21.6% a shekarar 2024.
Kasuwancin likitancin Sonoscape ya ƙunshi sassa da yawa, kuma ba a bayyana tsarin gida da na waje na kasuwancin endoscope daban. Adadin kasuwancin kasa da kasa gaba daya na kamfanin yana karuwa, daga yuan miliyan 500 a shekarar 2020 zuwa yuan miliyan 970 a shekarar 2024, kuma adadin kasuwancin kasa da kasa yana da kwanciyar hankali, tsakanin kashi 43% zuwa 48%.
Kwatanta kasuwancin duniya da Aohua da Sonoscape suka buɗe
( Yuan miliyan 100)
Yawan kasuwancin duniya da Aohua da Sonoscape suka bude
Matsayin riba
A matsayin manyan kamfanoni guda biyu na na'urorin lafiya masu sassaucin ra'ayi na cikin gida, Aohua da Sonoscape sun ci gaba da samun babban ribar riba tare da ingantattun samfuransu da damar kasuwanci. Jimillar ribar da Aohua ke samu a hankali ya karu daga kashi 67.4% a shekarar 2020 zuwa kashi 73.8% a shekarar 2023, amma zai ragu zuwa kashi 68.2% a shekarar 2024; Babban riba na Sonoscape ya karu a hankali daga 66.5% a cikin 2020 zuwa 69.4% a 2023, amma zai ragu zuwa 63.8% a 2024; Gabaɗayan babbar ribar Sonoscape ya ɗan yi ƙasa da na Aohua, amma ya samo asali ne saboda bambance-bambancen tsarin kasuwanci. Idan aka yi la'akari da kasuwancin endoscopy kawai, babbar riba ta Sonoscape ta karu daga 65.5% a cikin 2020 zuwa 74.4% a 2023, amma zai ragu zuwa 66.6% a 2024. Babban riba mai girma na kasuwancin endoscopy guda biyu yana kwatankwacinsa.
Kwatanta babban riba tsakanin Aohua da Sonoscape
R&D zuba jari
Duka Aohua da Sonoscape suna ba da mahimmanci ga bincike da haɓaka samfura. Kudin R&D na Aohua ya karu daga kashi 11.7% a shekarar 2017 zuwa kashi 21.8% a shekarar 2024. Adadin kudin R&D na Sonoscape ya kasance tsakanin kashi 18% zuwa 20% a cikin 'yan shekarun nan, amma a shekarar 2024, jarin R&D ya kara karuwa, ya kai kashi 23.5%.
Kwatanta kashe kuɗin R&D tsakanin Aohua da Sonoscape ( yuan miliyan)
Kwatanta hannun jarin ma'aikatan R&D tsakanin Aohua da Sonoscape
Dukansu Aohua da Sonoscape suna ba da muhimmiyar mahimmanci ga saka hannun jari a cikin aikin R&D. A cikin 'yan shekarun nan, rabon ma'aikatan R&D na Kaiili ya tsaya tsayin daka da kashi 24% -27% na yawan ma'aikata, yayin da rabon ma'aikatan R&D na Aohua ya tsaya tsayin daka da kashi 18% -24% na yawan ma'aikata.
Mu, Jiangxi Zhuoruihua Medical Instrument Co., Ltd., wani manufacturer ne a kasar Sin ƙware a cikin endoscopic consumables, kamarbiopsy forceps, hemoclip, polyp tarko, allurar sclerotherapy, fesa catheter, cytology goge, jagora, kwandon dawo da dutse, hanci biliary drainage catheter,urethra samun kumfakumaKumburin shiga urethra tare da tsotsada sauransu wadanda ake amfani da su sosai a cikiEMR, ESD, ERCP. Samfuran mu suna da takardar shedar CE, kuma tsire-tsire namu suna da takaddun ISO. An fitar da kayanmu zuwa Turai, Arewacin Amurka, Gabas ta Tsakiya da wani yanki na Asiya, kuma suna samun abokin ciniki yabo da yabo!
Lokacin aikawa: Yuli-14-2025